Integral Molecular News

Webinar presented by Integral Molecular and The Antibody Society – Harnessing Divergent Species to Access Difficult and Conserved Antibody Targets

Thursday, April 25, 2024
8 am PT, 11 am ET, 17:00 CET
View the recording

To exploit highly conserved and difficult drug targets, including GPCRs and ion channels, monoclonal antibody discovery efforts are increasingly relying on the advantages offered by divergent species such as rabbits, camelids, and chickens. Divergent host species enable robust immune responses against highly conserved binding sites and yield antibodies capable of penetrating functional pockets via long HCDR3 regions. Pan-reactive molecules are often produced by divergent hosts, and these antibodies can be tested in accessible animal models, offering a faster path to clinical development.

In this webinar, Dr. Ross Chambers will analyze gaps in therapeutic antibodies that stem from the historic use of mice and examine opportunities to exploit previously inaccessible targets through discovery in alternate species. Examples of preclinical and clinical-stage antibodies raised in divergent species will be highlighted, providing an overview of their success

Antibody Society and Integral Molecular webinar

View the recording

Upcoming Events

BIO International
June 3rd-6th, 2024
San Diego, CA
 
Immuno-Oncology Summit
Aug 7th-9th, 2024
Philadelphia, PA
 
Disease Prevention and Control Summit
Sep 5th-6th, 2024
Philadelphia, PA